Prednisone 5 mg

DRUG5 trials

Conditions

AllergyConjunctivitisMetastatic Castration-Resistant Prostate CancerProstate CancerProstatic Neoplasms, Castration-ResistantRheumatoid ArthritisRhinitisRhinoconjunctivitis

Phase 1

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

CompletedNCT01511536

SanofiProstate Cancer

Start: 2012-03-31End: 2014-12-31Updated: 2016-07-28

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

RecruitingNCT02861573

Merck Sharp & Dohme LLCMetastatic Castration-Resistant Prostate Cancer

Start: 2016-11-17End: 2028-07-24Target: 1200Updated: 2026-02-17

Phase 2

A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

CompletedNCT00938587

PfizerRheumatoid Arthritis

Start: 2009-10-07End: 2010-07-29Updated: 2023-11-22

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Active, not recruitingNCT03431350

Janssen Research & Development, LLCProstatic Neoplasms, Castration-Resistant

Start: 2018-03-02End: 2026-12-31Updated: 2026-03-25

Phase 3

Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)

CompletedNCT00562159

ALK-Abelló A/SAllergy, Conjunctivitis, Rhinitis +1

Start: 2007-11-30End: 2009-09-30Updated: 2017-03-03

2025-08-11

Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC).

Journal of Clinical Oncology2025-05-281 citations

Population Pharmacokinetics of Niraparib/Abiraterone Acetate Administered as Single-Agent Combination and Dual-Acting Tablets Plus Prednisone for Metastatic Castration-Resistant Prostate Cancer.

2025-02-28

PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers

Cell Reports Medicine2024-11-016 citations

Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D.

2024-06-253 citations

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.

2024-03-029 citations

Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.

Journal of Clinical Oncology2024-01-292 citations

Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.

Journal of Clinical Oncology2024-01-291 citations

Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.

Journal of Clinical Oncology2024-01-29

Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.

Journal of Clinical Oncology2024-01-29

Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study

European Urology Oncology2023-11-0710 citations

MP27-17 NIRAPARIB WITH ABIRATERONE ACETATE AND PREDNISONE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM THE PHASE 2 QUEST STUDY

The Journal of Urology2022-04-072 citations

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

European Urology2022-04-0674 citations

KEYNOTE-365 cohort I: Phase 1b/2 study of pembrolizumab combined with platinum-containing chemotherapy and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE).

Journal of Clinical Oncology2022-02-163 citations

KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab + lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).

Journal of Clinical Oncology2022-02-161 citations

KEYNOTE-365 cohorts G and H: Phase 1b/2 study of pembrolizumab + vibostolimab combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).

Journal of Clinical Oncology2022-02-161 citations

Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.

Journal of Clinical Oncology2022-02-16

351 KEYNOTE-365 cohort D: pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)

Regular and Young Investigator Award Abstracts2021-11-014 citations

347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of 22 months of follow-up

Regular and Young Investigator Award Abstracts2021-11-012 citations

419 Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F

Regular and Young Investigator Award Abstracts2021-11-012 citations

33 more papers not shown

Prednisone 5 mg

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers